Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/06—Emulsions
  • A61K8/062—Oil-in-water emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
  • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/63—Steroids; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/007—Preparations for dry skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• compositions comprising ceramide, polyglycerol carboxylic acid esters and cholesterol
• the invention relates to compositions comprising at least one ceramide, at least one polyglycerol carboxylic acid ester and cholesterol in specific ratios by weight.
• EP3117821 discloses a process for producing a ceramide dispersion composition in which a mixture of ceramide, non-ionic surfactant and polyhydric alcohol is heated to a temperature of equal to or higher than 100°C.
• EP2295032 discloses ceramide dispersions comprising natural ceramide and at least one surfactant, wherein the ceramide dispersions in the at least one surfactant comprise at least one polyglycerol fatty acid ester having an HLB of 10 to 16.
• EP975325 discloses a composition for topical application, comprising a combination of a free sphingoid base and a ceramide.
• US8710034 discloses compositions comprising ceramide and cholesterol for improving the barrier function of skin.
• US2006198800A1 discloses a skin care composition comprising: a safe and effective amount of at least one anti-wrinkle agent and a safe and effective amount of a natural peeling complex.
• the object of the invention was to provide ceramide-containing compositions which further improves the cosmetic properties of the ceramides present.
• the present invention therefore relates to a composition comprising at least one ceramide, at least one polyglycerol carboxylic acid ester and cholesterol in specific ratios by weight.
• the invention further relates to the use of the composition according to the invention for increasing the barrier function of skin.
• compositions according to the invention have increased storage stability and are thus slower to change in their nature overtime, particularly with regard to their viscosity, compared to ceramide-containing compositions according to the prior art.
• Another advantage of the present invention is that the compositions according to the invention tolerate a higher number of freeze-thaw steps without significant loss of viscosity, compared to ceramide-containing compositions according to the prior art.
• composition according to the invention is that the composition in formulations has superior sensory properties which lead to an improved skin feel and/or hair feel.
• composition according to the invention stimulates in vitro human follicular dermal papilla cells (HFDPCs) to proliferate, which in vivo equates to stimulation of hair growth.
• HFDPCs human follicular dermal papilla cells
• composition according to the invention has improved distributability compared to the individual components.
• composition according to the invention has improved absorption compared to the individual components.
• composition according to the invention has reduced oiliness compared to the individual components.
• composition according to the invention has reduced waxiness compared to the individual components.
• composition according to the invention has improved glidability compared to the individual components.
• composition according to the invention has reduced tackiness compared to the individual components.
• composition according to the invention has improved silkiness/velvetiness compared to the individual components.
• composition according to the invention improves skin roughness and skin smoothness more potently than ceramide-containing compositions according to the prior art.
• composition according to the invention regenerate a barrier damaged by SDS more strongly than ceramide-containing compositions according to the prior art.
• ceramide is understood to mean acylated sphingoid bases, where the sphingoid bases are preferably selected from sphingosine, sphinganine, 6-hydroxysphingosine and phytosphingosine.
• the “pH” in connection with the present invention is defined as the value which is measured for the relevant composition at 22°C after stirring for five minutes using a pH electrode calibrated in accordance with ISO 4319 (1977).
• polyglycerol carboxylic acid esters present according to the invention are mixtures of different substances; it is therefore clear to those skilled in the art that the numeric values specified are average values for the mixture.
• polyglycerol is to be understood as meaning a polyglycerol which may also comprise glycerol. Consequently, for the purposes of calculating amounts, masses and the like, any glycerol fraction should also be taken into consideration. Owing to its polymeric property, the polyglycerol is a statistical mixture of various compounds. Polyglycerol may have ether bonds formed between two primary, one primary and one secondary or else two secondary positions of the glycerol monomers. For this reason, the polyglycerol base skeleton does not usually consist exclusively of linearly linked glycerol units, but may also comprise branches and rings. For details see, for example, "Original synthesis of linear, branched and cyclic oligoglycerol standards" , Cassel et al., J. Org. Chem. 2001 , 875-896.
• the present invention therefore relates to a composition
• a composition comprising
• a preferred composition according to the invention is characterized in that the ratio by weight of all ceramides present to all polyglycerol carboxylic acid esters present is from 1 :1 to 1 :30, preferably from 1 :1 to 1 :25, particularly preferably from 1 :2 to 1 :20. It is preferred in accordance with the invention that the composition according to the invention is characterized in that it comprises
• D) at least one sphingoid base preferably selected from the group comprising sphingosine, sphinganine, 6-hydroxysphingosine, N-acetylphytosphingosine and phytosphingosine, especially phytosphingosine.
• Component D) is preferably present according to the invention in an amount of 0.01% by weight to 2.0% by weight, preferably 0.02% by weight to 1 % by weight, particularly preferably 0.02% by weight to 0.8% by weight, based on the total composition according to the invention.
• the ratio by weight of component A) to component D) in the composition according to the invention is preferably from 1 : 1 to 1 : 0.01 , preferably from 1 : 0.8 to 1 : 0.02, particularly preferably from 1 : 0.7 to 1 : 0.05.
• At least one free fatty acid preferably selected from the group of fatty acids having a chain length of 12 to 40, preferably 14 to 24, particularly preferably 16 to 22 carbon atoms.
• Component E) is preferably present according to the invention in an amount of 0.01% by weight to 3.0% by weight, preferably 0.05% by weight to 2.0% by weight, particularly preferably 0.1% by weight to 1 .0% by weight, based on the total composition according to the invention.
• the ratio by weight of component B) to component E) in the composition according to the invention is preferably from 1 : 0.001 to 1 : 1 , preferably from 1 : 0.01 to 1 : 0.5, particularly preferably from 1 : 0.02 to 1 : 0.1 .
• composition according to the invention is characterized in that said composition comprises 20% by weight to 99% by weight, preferably 40% by weight to 97% by weight, particularly preferably 50% by weight to 95% by weight water, based on the total composition. enthalt.
• compositions according to the invention are active ingredient concentrates having a high active content; a preferred composition according to the invention of this kind is characterized in that said composition comprises component A), B) and C) in a total amount of 1 .0% by weight to 25% by weight, preferably 2.0% by weight to 20% by weight, particularly preferably 4.0% by weight to 15% by weight, based on the total composition.
• compositions preferred in accordance with the invention comprise at least two ceramides, preferably at least three ceramides, particularly preferably precisely three ceramides.
• ceramides selected from the group comprising ceramide NP, ceramide AP, ceramide EOP, ceramide NDS, ceramide ADS, ceramide EODS, ceramide NS, ceramide AS, ceramide EOS, ceramide NH, ceramide AH and ceramide EOH, preferably selected from the group comprising ceramide NP, ceramide AP, ceramide NS, ceramide EOP and ceramide EOS.
• compositions preferred in accordance with the invention are characterized in that the polyglycerol carboxylic acid ester of component B is composed of a polycerol having a degree of polymerization of 2.0 to 25, preferably of 2.5 to 20, particularly preferably of 3.0 to 15.
• the degree of polymerization of the polyglycerol A/ is calculated via its hydroxyl number (OHN, in mg KOH/g) according to the following formula:
• Suitable methods for determining the hydroxyl number are particularly those according to DGF C-V 17 a (53), Ph. Eur. 2.5.3 Method A and DIN 53240.
• composition of the present invention is preferably characterized in that the polyglycerol carboxylic acid ester of component B) is composed of at least one carboxylic acid selected from fatty acids, in particular having 12 to 26, preferably 14 to 24, particularly preferably 16 to 22 carbon atoms.
• composition of the present invention is preferably characterized in that the polyglycerol carboxylic acid ester of component B) does not contain any dicarboxylic, preferably any polycarboxylic, acid esterified into the polyglycerol carboxylic acid ester.
• the fatty acids are generally unbranched and consist of an even number of carbon atoms. Any double bonds have cis configuration.
• Examples of fatty acids are: caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, isostearic acid, stearic acid, 12- hydroxystearic acid, dihydroxystearic acid, oleic acid, linoleic acid, linolenic acid, petroselic acid, elaidic acid, arachic acid, behenic acid, erucic acid, gadoleic acid, linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid.
• the at least one carboxylic acid from which the polyglycerol carboxylic acid ester of component B) is composed according to the invention is particularly preferably selected from palmitic acid, stearic acid and behenic acid.
• the polyglycerol carboxylic acid ester of component B) is composed of mixtures of fatty acids, especially mixtures of at least two selected from palmitic acid, stearic acid and behenic acid, wherein the sum of these makes up at least 60% by weight, preferably at least 75% by weight, even more preferably at least at least 85% by weight, based on all fatty acids present in the mixture.
• the ratio by weight of palmitic acid to stearic acid to behenic acid is from 1 .0:3.0 to 1 .0:3.0 to 1 .0, preferably from 1 .2:2.1 to 1 .4:2.4 to 1 .0.
• the polyglycerol carboxylic acid ester present in component B) according to the invention can be provided in accordance with the invention by mixing different separately obtained polyglycerol carboxylic acid esters.
• a polyglycerol palmitate with a polycerol behenate can be provided in accordance with the invention by mixing different separately obtained polyglycerol carboxylic acid esters.
• the polyglycerol carboxylic acid ester present in component B) according to the invention is characterized preferably in accordance with the invention in that it has a saponification number of 20 to 199 mg KOH/g, preferably 30 to 100 mg KOH/g, particularly preferably 40 to 70 mg KOH/g. By this, an extraordinary dispersion stability is assured.
• the determination of the saponification number is carried out by those skilled in the art according to DGF C-V 3 or DIN EN ISO 3681 .
• compositions according to the invention are particularly formulations, especially in the form of a cosmetic, pharmaceutical or dermatological formulation.
• formulations can be produced by mixing in which the active ingredient concentration is reduced compared to the aforementioned concentrates; such an alternative, preferred composition according to the invention is characterized in that it comprises component A), B) and C) in a total amount of 0.01 % by weight to 1 .25% by weight, preferably 0.01 % by weight to 1 .00% by weight, particularly preferably 0.02% by weight to 1 .00% by weight, based on the total composition, and is particularly preferably a cosmetic, pharmaceutical or dermatological formulation.
• the formulations according to the invention can further comprise at least one additional component selected from the group of emollients, emulsifiers, thickeners/viscosity regulators/stabilizers, UV light protection filters, antioxidants, hydrotropes (or polyols), solids and fillers, film formers, pearlescence additives, deodorant and antiperspirant active ingredients, insect repellents, self-tanning agents, preservatives, conditioning agents, perfumes, dyes, odour absorbers, cosmetic active ingredients, care additives, superfatting agents, solvents.
• Typical boundary formulations for the respective applications are known prior art and are contained for example in the brochures of the manufacturers of the particular base and active ingredients. These existing formulations can generally be adopted unchanged. However, if required, for adjustment and optimization, the desired modifications can be undertaken by simple tests without complication.
• compositions of the present invention which are preferred according to the invention are emulsions, in particular oil-in-water emulsions.
• a particularly preferred composition according to the invention is characterized in that said composition has a pH in the range of 4.0 to 8.0, preferably 4.5 to 7.4 particularly preferably 5.0 to 7.2.
• the present invention further relates to the use of a composition according to the invention for increasing the barrier function of skin.
• Figure 1 LDH concentration in the supernatant of the skin models, measured 24 h after application of the test formulations to the skin models previously damaged with SDS.
• Figure 2 Interleukin 1a concentration in the supernatant of the skin models, measured 24 h after application of the test formulations to the skin models previously damaged with SDS.
• FIG. 3 The diagram shows the difference of the SEsm parameter to the starting value TO. A decrease in SEsm is equivalent to an improvement in skin smoothness.
• Figure 4 The diagram shows the difference of the roughness parameter to the starting value TO after one week's application of the test formulations.
• Figure 5 The diagram shows the difference of roughness parameter to the starting value TO after two weeks’ application of the test formulations.
• Example 1 Synthesis of the polyglycerol carboxylic acid esters used (polyglycerol-6 esterified with C16-,C18- and C22-carboxylic acids)
• Example 1b Synthesis of the polyglycerol carboxylic acid esters used (polyglycerol-6 esterified with C16- and C18-carboxylic acids)
• Example 1d Synthesis of the polyglycerol carboxylic acid esters used (polyglycerol-10 esterified with C8-, C10-, C16- and C18-carboxylic acids)
• Example A is inventive
• Example B corresponds to the prior art as described in Example 9 of US2006198800.
• the test described below is carried out on epidermis skin models (EpiCS, SkinlnVitro, Troisdorf). These three-dimensional skin models consist of epidermis, proliferating keratinocytes and a stratum corneum having an intact barrier function.
• the skin models are damaged with 0.325% aqueous sodium dodecyl sulfate solution (SDS) for 40 minutes.
• SDS sodium dodecyl sulfate solution
• the test formulations are then applied.
• the test formulations used are Example A* and Example B at a concentration of 0.1 , 0.3 and 0.5% in water.
• a vehicle is also tested. This is Ultrapure water.
• the application duration is 1 hour.
• Figure 2 shoes the concentration of interleukin 1a (IL-1 a) 24 hours after application of the test formulations to the skin models previously damaged with SDS.
• An inflammatory process is set in motion by damage to the skin barrier with SDS, which is evidenced by the sharp increase in the concentration of IL-1 a.
• the vehicle Ultrapure water
• SDS + vehicle cannot stop this inflammatory process
• the expression of the IL-1 a inflammatory marker is significantly reduced.
• this goes back down to the level of the undamaged skin models (vehicle); in test formulation B the expression of IL-1 a is also distinctly reduced but it is significantly higher than in Example A.
• Example 3 in vivo study on skin dryness
• test formulations and the control are distributed according to the random principle but so that all test formulations and the control are tested on 20 volunteers.
• test formulations are applied twice daily over a period of two weeks. Prior to the start of application and after one and after two weeks, images of the inner forearms are recorded.
• a Visioscan VC 98 camera from CK electronic GmbH is used for this purpose. This is a specific camera which records enlarged black and white images of the skin surface.
• the roughness parameters R1 , R2, R3, R4 and R5 and the SEsm parameter are then determined with the aid of an integrated software. This parameter is proportional to the width and shape of the wrinkles. A more detailed description for calculating this parameter is found in the manual of the Visioscan VC 98 camera, Version “VC 98 english FireWire 04/2005 DK”.
• the SEsm parameter has to decrease if skin smoothness is to improve.
• the roughness parameters R1 , R2, R3, R4 and R5 originally come from the metal industry and are defined in the provisions of DIN 4762-4768 as Ra-Rz. In the Visioscan software, these results are expressed as an index (in grey scales) and are linked to the original Ra-Rz values.
• the parameters have the following meanings:
• the following table shows the composition of the test formulation. This is an O/W lotion based on commercially available cosmetic raw materials. The following steps are required to prepare the formulation:
• Phase A and B are heated to 70°C.
• Phase B is added to phase A without stirring.
• the mixture is briefly homogenized once more.
• the emulsion is further cooled to 30°C with stirring. Below 40°C, phase D, E and F are added.
• both test formulations are capable of reducing skin roughness, whereas the vehicle shows no efficacy.
• formulation A according to the invention improves skin roughness more than formulation B of the prior art.
• Example A shows improved efficacy compared to Example B of the prior art with regard to improvement in skin smoothness and reduction of skin roughness in volunteers with dry skin.
• the formulations are prepared as follows:
• Phase A and phase C are heated to 90°C. Phase A is then added to phase C with stirring. This pre-emulsion is then homogenized, for example using an Ultra Turrax. The emulsion is cooled to 40°C with gentle stirring and the preservative is added. The mixture is then further cooled to 30°C with stirring.
• Example 4 Emulsion stability
• the formulations listed below were prepared as follows: Polyglycerol ester, ceramides, phytosphingosine, behenic acid, glycerol monostearates, cetearyl alcohol and triethyl citrate are heated to 85°C (phase A). The water is also heated to 85 °C. Phase A is then added to the water with stirring. This pre-emulsion is then homogenized with a rotor-stator homogenizer. The emulsion is cooled to 30°C with gentle stirring and the sodium levulinate and the potassium sorbate are added.
• Formulations 18 to 21 are formed as homogeneous, stable and lamellar dispersions. Formulations 22 to 27 turned out to appear inhomogeneous already while using the rotor-stator homogenizer and phase separation occurred instantly.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Dispersion Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Emergency Medicine (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Cosmetics (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=72826694

Family Applications (1)

Country Status (6)

Cited By (2)

Families Citing this family (2)

Citations (7)

Family Cites Families (5)

• 2020
  • 2020-10-09 EP EP20200973.4A patent/EP3981378A1/de not_active Withdrawn
• 2021
  • 2021-10-04 WO PCT/EP2021/077250 patent/WO2022073909A1/en not_active Ceased
  • 2021-10-04 CN CN202180067989.6A patent/CN116261445B/zh active Active
  • 2021-10-04 US US18/248,224 patent/US20230414460A1/en active Pending
  • 2021-10-04 KR KR1020237012071A patent/KR20230084503A/ko active Pending
  • 2021-10-04 EP EP21785905.7A patent/EP4225260A1/en active Pending
  • 2021-10-04 JP JP2023521675A patent/JP2023546380A/ja active Pending

Patent Citations (8)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events